The U.S. benign prostatic hyperplasia surgical treatment market size is expected to reach USD 1,232.65 million by 2034, according to a new study by Polaris Market Research. The report “U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of Prostate (TURP), Prostatic Urethral Lift], By End User; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Benign prostatic hyperplasia surgical treatment refers to clinically guided procedures aimed at relieving urinary symptoms associated with prostate gland enlargement in aging men. The growing preference for outpatient and minimally invasive surgery approaches, which offer shorter hospital stays and quicker recovery times, is driving market growth. This shift is driven by growing patient awareness, payer support for cost-effective interventions, and the healthcare system’s focus on enhancing procedural efficiency. As a result, there is a growing acceptance of advanced surgical techniques that balance clinical outcomes and patient comfort.
Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-benign-prostatic-hyperplasia-surgical-treatment-market/request-for-sample
The rapid integration of advanced technologies drives the U.S. BPH surgical treatment market, supporting precision and consistency in surgical care. Innovations in urology tools, real-time imaging, surgical robot, and energy-based devices are streamlining treatment workflows and improving patient outcomes. These technological advancements are encouraging the adoption of evidence-based practices and personalized care strategies, reinforcing the market’s shift toward high-value, outcome-oriented healthcare delivery.
By Type Outlook (Revenue, USD Million, 2020–2034)
By End User Outlook (Revenue, USD Million, 2020–2034)